USE OF NORMAL TISSUE COMPLICATION PROBABILITY MODELS IN THE CLINIC
|
|
- Cecily Wood
- 5 years ago
- Views:
Transcription
1 doi: /j.ijrobp Int. J. Radiation Oncology Biol. Phys., Vol. 76, No. 3, Supplement, pp. S10 S19, 2010 Copyright Ó 2010 Elsevier Inc. Printed in the USA. All rights reserved /10/$ see front matter INTRODUCTORY PAPER USE OF NORMAL TISSUE COMPLICATION PROBABILITY MODELS IN THE CLINIC LAWRENCE B. MARKS, M.D.,* ELLEN D. YORKE, PH.D., y ANDREW JACKSON, PH.D., y RANDALL K. TEN HAKEN, PH.D., z LOUIS S. CONSTINE, M.D., x AVRAHAM EISBRUCH, M.D., z SØREN M. BENTZEN, PH.D., k JIHO NAM, M.D.,* AND JOSEPH O. DEASY, PH.D. { *Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC; y Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY; z Department of Radiation Oncology, University of Michigan, Ann Arbor, MI; x Department of Radiation Oncology, University of Rochester Cancer Center, Rochester, NY; k Department of Human Oncology, University of Wisconsin School of Medicine, Madison, WI; and { Department of Radiation Oncology, Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO The Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) review summarizes the currently available three-dimensional dose/volume/outcome data to update and refine the normal tissue dose/volume tolerance guidelines provided by the classic Emami et al. paper published in A clinician s view on using the QUANTEC information in a responsible manner is presented along with a description of the most commonly used normal tissue complication probability (NTCP) models. A summary of organ-specific dose/volume/outcome data, based on the QUANTEC reviews, is included. Ó 2010 Elsevier Inc. QUANTEC, NTCP. INTRODUCTION Historically, radiation therapy (RT) fields/doses were selected empirically, based largely on experience. Physicians relied on clinical intuition to select field sizes/doses. They understood that these empiric guidelines were imprecise and did not fully reflect the underlying anatomy, physiology, and dosimetry. A great promise of three-dimensional (3D) treatment planning was quantitative correlates of doses/volumes with clinical outcomes. This promise was partly delivered. When 3D dosimetric information became widely available, guidelines were needed to help physicians predict the relative safety of proposed treatment plans, although only limited data were available. In 1991, investigators pooled their clinical experience, judgment, and information regarding partial organ tolerance doses, and produced the Emami paper (1). While Emami is often criticized, the paper clearly stated the uncertainties and limitations in its recommendations, and it is widely admired for addressing a clinical need. During the last 18 years, numerous studies reported associations between dosimetric parameters and normal tissue outcomes. The QUANTEC (quantitative analysis of normal tissue effects in the clinic) articles summarize the available data to update/refine the estimates provided by Emami et al. A central goal of QUANTEC is to summarize this information in a clinically useful manner. We hope the information will improve patient care by providing clinicians and treatment planners with tools to estimate optimal/acceptable 3D dose distributions. We hope that at least some of the summary tables, graphs, and models presented will be reproduced and posted in resident workrooms, dosimetry planning areas, and physician offices, as is currently done with the Emami et al. tables. The information provided by QUANTEC is not ideal, and care must be taken to apply it correctly in the clinic. We herein present a clinician s view on using the QUANTEC information in a responsible manner, highlighting the diverse type of limitations of the presented data. LIMITATIONS INHERENT IN EXTRACTING DATA FROM THE LITERATURE The information presented is largely extracted from publications. Because different investigators often present information differently (e.g., actuarial vs. crude complication rates), pooling data from multiple studies may be inaccurate. Reprint requests to: Lawrence B. Marks, M.D., Department of Radiation Oncology, Box 7512 University of North Carolina, Chapel Hill, NC Tel: (919) ; Fax: (919) ; marks@med.unc.edu Conflict of interest: none. Acknowledgments The authors express special thanks to Jessica Hubbs and Janet Bailey for their assistance in the preparation of S10 this manuscript. Partially supported by National Institutes of Health grants CA85181 (J.O.D.) and CA69579 (L.B.M.) and by a grant from the Lance Armstrong Foundation (L.B.M.). Received Jan 6, 2009, and in revised form July 1, Accepted for publication July 2, 2009.
2 Use of NTCP models in the clinic d L. B. MARKS et al. S11 Summary tables are often included to help the reader better understand the primary data. LIMITATIONS OF PREDICTIVE MODELS Some studies use models to estimate the complication risk. Care should be taken when applying models, especially when clinical dose/volume parameters are beyond the range of data used to generate the model/parameters. Models and dose/volume recommendations are only as good as the data available. Typically, they are based on dose volume histograms (DVHs). DVHs are not ideal representations of the 3D doses as they discard all organ-specific spatial information (and hence assume all regions are of equal functional importance), and often do not consider fraction size variations. They are usually based on a single planning computed tomography (CT) scan that does not account for anatomic variations during therapy (Fig. 1). Interinstitutional/physician differences in image segmentation, dose calculation, patient populations, and preferred beam arrangements may limit model exportability. Before introducing a predictive model into a clinical practice, it is prudent to assess if its predictions make sense in regard to that clinic s treatment plans and experience. EVOLVING FRACTIONATION SCHEDULES RT-induced normal tissue responses are fraction size dependent. Throughout the QUANTEC reviews, this variable is acknowledged and, where possible, considered by making adjustments for fraction size based on the linear quadratic (LQ) model. Nevertheless, a/b ratios are uncertain. Particular care must be taken when QUANTEC information is applied to stereotactic RT, where the fraction size is much different than that in the cited literature. For very novel fractionations, even the validity of the LQ model is questioned (2). Even when the prescribed tumor dose is conventionally fractionated, the fraction size seen by the normal tissue may have varied over time. When Emami was published, most external RT was delivered with opposing fields, and shrinking field techniques the normal tissue was irradiated with a fairly uniform fraction size. Modern techniques often use multiple beams (with or without concurrent boosts); the volume of normal tissue exposed to low doses is often increased and the dose is delivered at fraction sizes ranging from z0to the prescribed fraction size. COMBINED MODALITY THERAPY Use of sequential/concurrent chemotherapy/rt is increasing for many tumors. Concurrent chemotherapy is typically believed to exacerbate the severity of normal tissue reactions, but data quantifying this is often lacking. Even when such data are available, the chemotherapy doses, schedules and agents which may influence outcomes are in evolution. HOST FACTORS Fig. 1. A three-dimensional dose distribution is reduced to a two-dimensional (2D) dose volume histogram (DVH) by discarding all spatial, anatomic and physiologic data. The 2D graph is then further reduced to a single value of merit, such as the mean dose, the percent of the organ receiving $20 Gy (V20), or a model-based normal tissue complication probability (NTCP). Host factors (e.g., chronic liver disease, genetic, lifestyle) may affect dose response relationships and are partly responsible for the shallowness of these relationships in the patient population. It is likely that incorporating these factors, when they are known, will produce better models/correlations/predictors of toxicity. BALANCING THE RISKS TO DIFFERENT ORGANS Different morbidities vary in their clinical significance. Grade 2 toxicity has a different clinical meaning for the esophagus than for the rectum. Furthermore, different patients may have different levels of acceptance for injuries. When comparing competing treatment plans, there is usually a tradeoff; for example, should we accept a certain dose to the lung or to the esophagus? For most cases, modern treatments will redistribute, not eliminate, the dose to normal tissue. The fundamental problem of treatment planning is how to balance exposure of one organ against that of another. Unfortunately, there is no objective way to do this. Investigators have considered the risks to multiple organs, and computed the probability of uncomplicated tumor control (3 5). Others have attempted to incorporate the relative importance of different toxicities by considering their impact on patients quality of life. This approach generates a global figure of merit such as the quality of life adjusted tumor control probability (6, 7). The utility of this approach, although conceptually attractive, is not clear. FOLLOW-UP DURATION If dose effect relationships for a late complication are derived from a patient population with very poor prognosis, they may be limited by lack of long-term follow-up, and not applicable to patients with a better prognosis (e.g., applying brain toxicity from patients with high-grade glioma to patients with low-grade tumors). The risk of normal tissue complication occurs in the context of a patient s expected longevity. Radiation therapy is an effective anti-cancer therapy and can provide good
3 S12 I. J. Radiation Oncology d Biology d Physics Volume 76, Number 3, Supplement, 2010 palliation for patients with recurrent/metastatic/incurable disease. In these settings, concern for late normal tissue reactions often should not limit the application of RT. For example, reirradiation of the whole brain for recurrent brain metastases to cumulative doses well above tolerance can provide palliation for these challenging cases (8 10) for which concern about late toxicity may be unnecessary. Similarly, RT for locally advanced lung cancers may routinely exceed the normal dose limits for lung and heart. In these instances, there typically are no good alternative therapies available. Withholding thoracic RT because of the risk of pericarditis or pneumonitis may not be therapeutically rational. These concerns are most applicable to recently trained radiation oncologists who are accustomed to using 3D dosimetric information for most of their clinical decision making. They may be uncomfortable in clinical settings where large RT fields need to be applied without 3D dosimetry in order to provide palliative effect. It is the physician s responsibility to tell dosimetrists/physicists when it is appropriate to proceed with treatment without a formal 3D dose/volume assessment and/or suspend the conventional departmental dose/ volume guidelines. RELATING WHOLE TREATMENT DVHS WITH ACUTE TOXICITIES For some organs, a relevant acute toxicity may occur during the course of RT (i.e., before the delivery of the entire RT course). Relating the incidence of such acute events to a DVH that reflects the whole treatment course may be somewhat illogical. It might be preferable to try to relate acute events to the dose delivered before symptom onset (or even to doses received a number of days before symptom onset, if there is a known latency time). If a consistent set of treatment fields is used throughout the entire course of treatment (e.g., no field reductions), the whole course DVH might be a reasonable surrogate for the 3D doses delivered before acute symptom onset. Therefore, in these situations, it still might be a reasonable to relate the risk of acute events to a DVH that reflects the whole treatment course. However, field arrangements often change during therapy, thus altering the dose/volume parameters for the target organ (e.g., initial AP-PA fields plus a subsequent off-cord boost). In these situations, the whole-course DVH is less likely to be a reasonable surrogate for the 3D doses delivered prior to the acute toxicity. Thus, some dose/volume/outcomes analyses for acute endpoints that consider the so-called wholecourse DVH may be suspect. Further complicating the issue is the fact that the duration of symptoms (that may also influence the scoring of toxicity), may be affected by RT dose delivered after the onset of symptoms. In this regard, the whole-course DVH may indeed be reasonable to consider in dose/volume/outcomes analyses. A similar concern may apply for analyses of late effects. If a late toxicity results from a severe acute toxicity occurring during the course of RT, relating that late event to the whole-course DVH may also be suboptimal. TUMOR COVERAGE VS. NORMAL TISSUE RISK For most curative patients, a marginal miss is more serious than a normal tissue complication. For many tumors, recurrences are difficult to manage, cause severe morbidity, and usually result in mortality. Target coverage should generally not be compromised to reduce the normal tissue risks. This is exemplified by the experience from Israel in treating orbital lymphomas. In 24 tumors treated in 23 patients, intraorbital recurrence was seen in four of 12 (33%) of the tumors treated with conformal fields (including the radiographically defined gross tumor with margin), vs. none of the 12 tumors treated with conventional whole-orbit techniques (11). Similarly, investigators at Washington University noted a higher relapse rate in lung cancers closer to the spinal cord; perhaps reflecting compromised GTV coverage because of spinal cord protection (Ref. 12 and personal communication from J. Deasy, 2008). Engels et al. noted a reduction in 5-year biochemical disease-free survival rate (from 91% to 58%) in patients irradiated for prostate cancer with the addition of implanted seeds for localization, and tighter PTV margins, with the intent of reducing exposure to surrounding normal tissues (13). The use of improved diagnostic imaging, and improved immobilization and image guidance during RT, may facilitate a more realistic PTV margin to be applied safely. APPLICABILITY TO CHILDREN In the young, a mosaic of tissues develop at different rates and temporal sequences. In adults, the same tissues are in a steady state with relatively slow cell renewal kinetics. The vulnerability of tissues to RT typically increases during the periods of rapid proliferation. Consequently, generalizing data from adult to pediatric populations is problematic and requires caution. Ideally, specific data from investigations on children should be used to predict risks in this population. UNDERSTANDING THE BASICS OF NTCP MODELS Despite these caveats, model-based risk estimates are a reality. Physicians routinely use models, in their broadest sense, to make treatment decisions. Use of metrics such as the mean lung dose, and cord maximum dose to estimate risks are models, albeit simple ones. We present a primer regarding the basic principles of NTCP models. Generally, NTCP models attempt to reduce complicated dosimetric and anatomic information to a single risk measure. Most models fall into one of three categories: DVH-reduction models, tissue architecture models, and multiple-metric (i.e. multimetric) models. DVH-reduction models Although most applications of DVH reduction models are to nonuniform dose distributions, they are based on estimated complication probability under uniform irradiation. A doseresponse for uniform irradiation is described by a mathematical function with at least two parameters: for example TD50, which denotes the dose for 50% complication probability, and m, which is inversely proportional to the slope at the
4 Use of NTCP models in the clinic d L. B. MARKS et al. S13 steepest part of the response curve. For a patient cohort with diverse radiosensitivities, the response curve is shallower (larger m) than for a biologically similar population receiving the same treatment (14). Various S-shaped functions are used to fit dose-response data, including the probit function used by Lyman (below). To account for the dose heterogeneity typical of parallel opposed beam irradiation (partial organ uniform irradiation), Jolles (15) described tissue tolerance as a power law of the fractional volume irradiated: DðV irradiated Þ¼D n Vreference V reference ; [1] ðv irradiated Þ Here V reference is the reference volume and V irradiated is the uniformly irradiated volume. D is the corresponding tolerance doses, representing a chosen level on the dose response curve, such as TD50. The parameter n controls the volume effect. Lyman (16) used this power law model to define the risks associated with partial organ volume uniform irradiation. From Eq. 1, decreasing the irradiated volume fraction shifts the dose response curve (TD50) to higher doses by a factor of the irradiated fractional volume raised to the power negative n. The effect of different n values on tolerance dose is shown in Fig. 2. For example, if the n parameter equals 1, then the TD50 of irradiation for one half of the volume is expected to increase by a factor of 2, whereas if the n parameter is 0.5, TD50 for irradiation of one half the volume would increase by a factor of the square root of 2. To generalize this to clinically realistic, heterogeneous dose distributions, a summary statistic the generalized equivalent uniform dose (geud) is often introduced (17, 18). The geud is the dose that, if given uniformly to the entire organ, is believed to yield the same complication rate as the true dose distribution. The geud is computed by summing over all voxels in the organ: n 1 geud ¼ ðd 1=n 1 þ d 1=n 2 þ. þ d 1=n N N Voxels Þ : [2] voxels Here N Voxels is the number of equi-volume voxels, and d i is the dose to the i th voxel. The geud equation is consistent with the power-law assumption. Together, the geud equation and the Lyman assumptions are often referred to as the Lyman-Kutcher-Burman (LKB) model (16, 18 20). Note that some analyses use the parameter n, and some use the parameter a, equal to 1/n. Both are shown in Fig. 2. When n is small (and a is large), changes in irradiated volume make only a modest change in relative tolerance whereas, as n gets larger (and a gets smaller), the tolerance dose depends strongly on the irradiated volume fraction. Serial vs. parallel complication endpoints There have been efforts to devise mechanistic models that ascribe the volume dependence of some complications to disruption of the organ s functional architecture by RT (21 23). Fig. 2. As the (idealized) irradiated organ fraction decreases, the tolerance dose (D) increases, more so for larger values of n or smaller values of a (=1/n). V Reference represents the reference volume (usually the full organ volume), and V Irradiated represents the volume irradiated. In so-called parallel complications, subvolumes of the organ function relatively independently. Sufficiently small portions of the organ can be damaged without clinical effect; the complication is observed only after more than a critical volume is damaged. Parallel complications have large volume effects, and for this reason they are often likened to LKB models with n z 1 (as is found in analyses of liver, lung, and kidney complications). More detailed models exist, including models employing the concept of a functional reserve, representing a hypothesized fraction of organ function that can be lost before a complication is likely (23). In contrast, serial complications occur when even a small portion of the organ suffers damage. Here, n is small (e.g., z 0.1 for late rectal bleeding). Serial complications are most affected by the hottest portion of the DVH. More detailed models exist for this type of endpoint as well, including models that make explicit the size of small subunits, all of which need to be preserved to avoid a complication (23). Figure 3 shows how different parts of an example DVH contribute to the overall geud as n varies. Note that: (a) the lowest value of n results in the highest geud corresponding to the hottest point on the DVH (more appropriate for serial-like endpoints), and (b) the lower dose bins contribute more when n approaches 1 (more appropriate for parallel-like endpoints). Multimetric models Clinicians frequently estimate complication risk via a single DVH point based on a statistically significant dose/volume cut-point reported in one or more studies. An example is the often-used V20 (percentage of lung receiving >20 Gy) as a predictor of radiation pneumonitis (24). However, such single volume threshold rules are overly simple, and often easily manipulated by the treatment planner, or by the optimization software. Optimizing based on such a threshold may introduce a kink in one part of the DVH to achieve a desired threshold value, while inadequately constraining the rest. An infinite number of very different dose distributions (some likely with very different risks) can have the same V20. The same is true for any
5 S14 I. J. Radiation Oncology d Biology d Physics Volume 76, Number 3, Supplement, 2010 Fig. 3. Volume effect parameter. The effect of changing the n parameter (= 1/a) in the Lyman model with the generalized equivalent uniform dose equation to compute normal tissue complication probability (NTCP) is shown. Starting with a (real) rectal dose volume histogram (DVH) computed for an intensity-modulated radiation therapy (IMRT) prostate patient plan (upper left), the DVH is first transformed into a single number by the generalized equivalent uniform dose (geud) equation that weights dose values exponentially. Lower figure shows the cumulative contribution of each part of the DVH to the overall geud for all bins below the given dose value. As one can see, if a is set to 1 (rightmost curve), geud would equal the mean dose (e.g., for parallel organs), and many voxels with doses as low as 20 to 30 Gy contribute significantly to the geud and therefore may increase the final NTCP value (although contributions are proportional to dose, so higher dose still does contribute more for the same volume). As n decreases, the value of geud is a determined mainly by the highest dose voxels (e.g., for series organs). Typical clinical values for late rectal bleeding are n z 0.1. Unfortunately, investigators sometimes report a (especially when discussing the geud) and other-times use n, where n=1/a. DVH-reduction scheme, including the LKB models; markedly different-looking DVHs can yield the same NTCP. However, models that consider a larger fraction of the DVH are less easily manipulated (and may be more radiobiologically logical) than are the threshold models that consider only one point on the DVH. Nonetheless, reports correlating single DVH point thresholds to toxicity are common and are often included in the QUANTEC reviews. The more robust multimetric approach selects several univariate-significant dosimetric features of the dose distribution (e.g., multiple V dose values) as well as medical variables and use multivariate analysis together with sophisticated statistical methods or machine learning algorithms to pick out the most significant combinations (25). In-depth discussions of this topic can be found in reviews elsewhere (26 29). SUMMARY A major goal of this issue of the Journal is to provide practical clinical guidance for physicians and treatment planners. The information presented is not perfect, as evidenced by the multiple caveats above. The lack of good predictors is somewhat unsettling. Nevertheless, the QUANTEC papers present a valuable review. Over time, with the help of new studies guided by new physical, statistical and biological technologies, we hope to be able to update this information so that patient care can be continually improved. With the multiple caveats outlined above in mind, a limited summary of available organ-specific dose/volume/outcome data is provided in Table 1. This is not meant to replace the detailed information provided in the individual organ-specific reviews. Treatment planners and physicians are encouraged to read the individual papers to understand the origin, certainty, and nuances that apply to the dose/volume/outcome data provided in the summary table. In general, the dose/volume/outcome data provided in the summary table are associated with generally-regarded clinically acceptable rates of injury; for example, low rates for severe injury (e.g., brain necrosis), and higher rates of less severe endpoints (e.g., erectile dysfunction). Thus, these are dose/volume parameters that might be widely applied in clinical practice. Obviously many clinical situations require treatments that exceed the dose/volume values shown. Where practical, some dose response data are included as well. Furthermore, most of the data in the table is based on conventionally fractionated radiation using conventional techniques, and may or may not be applicable in other settings.
6 Table 1. QUANTEC Summary: Approximate Dose/Volume/Outcome Data for Several Organs Following Conventional Fractionation (Unless Otherwise Noted)* Organ Volume segmented Irradiation type (partial organ unless otherwise stated) y Endpoint Dose (Gy), or dose/volume parameters y Rate (%) Notes on dose/volume parameters Brain Whole organ 3D-CRT Symptomatic necrosis Dmax <60 <3 Data at 72 and 90 Gy, extrapolated Whole organ 3D-CRT Symptomatic necrosis Dmax = 72 5 from BED models Whole organ 3D-CRT Symptomatic necrosis Dmax = Whole organ SRS (single fraction) Symptomatic necrosis V12 <5 10 cc <20 Rapid rise when V12 > 5 10 cc Brain stem Whole organ Whole organ Permanent cranial neuropathy or necrosis Whole organ 3D-CRT Permanent cranial neuropathy or necrosis Dmax <54 <5 D1 10 cc k #59 <5 Optic nerve / chiasm Whole organ 3D-CRT Permanent cranial neuropathy or necrosis Whole organ SRS (single fraction) Permanent cranial neuropathy or necrosis Dmax <64 <5 Point dose <<1 cc Dmax <12.5 <5 For patients with acoustic tumors Whole organ 3D-CRT Optic neuropathy Dmax <55 <3 Given the small size, 3D CRT is often Whole organ 3D-CRT Optic neuropathy Dmax whole organ zz Whole organ 3D-CRT Optic neuropathy Dmax >60 >7-20 Whole organ SRS (single fraction) Optic neuropathy Dmax <12 <10 Spinal cord Partial organ 3D-CRT Myelopathy Dmax = Including full cord cross-section Partial organ 3D-CRT Myelopathy Dmax = 60 6 Partial organ 3D-CRT Myelopathy Dmax = Partial organ SRS (single fraction) Myelopathy Dmax = 13 1 Partial cord cross-section irradiated Partial organ SRS (hypofraction) Myelopathy Dmax = fractions, partial cord cross-section irradiated Cochlea Whole organ 3D-CRT Sensory neural hearing loss Mean dose #45 <30 Mean dose to cochlear, hearing at 4 khz Parotid Whole organ SRS (single fraction) Sensory neural hearing loss Prescription dose #14 <25 Serviceable hearing Bilateral whole parotid glands Unilateral whole parotid gland 3D-CRT 3D-CRT Long term parotid salivary function reduced to <25% of pre-rt level Long term parotid salivary function reduced to <25% of pre-rt level Mean dose <25 <20 For combined parotid glands { Mean dose <20 <20 For single parotid gland. At least one parotid gland spared to <20 Gy { (Continued) Use of NTCP models in the clinic d L. B. MARKS et al. S15
7 Organ Pharynx Table 1. QUANTEC Summary: Approximate Dose/Volume/Outcome Data for Several Organs Following Conventional Fractionation (Unless Otherwise Noted)* (Continued) Volume segmented Bilateral whole parotid glands Pharyngeal constrictors Irradiation type (partial organ unless otherwise stated) y 3D-CRT Whole organ Endpoint Long term parotid salivary function reduced to <25% of pre-rt level Symptomatic dysphagia and aspiration Dose (Gy), or dose/volume parameters y Rate (%) Notes on dose/volume parameters Mean dose <39 <50 For combined parotid glands (per Fig. 3 in paper) { Mean dose <50 <20 Based on Section B4 in paper Larynx Whole organ 3D-CRT Vocal dysfunction Dmax <66 <20 With chemotherapy, based on single study (see Section A4.2 in paper) Whole organ 3D-CRT Aspiration Mean dose <50 <30 With chemotherapy, based on single study (see Fig. 1 in paper) Whole organ 3D-CRT Edema Mean dose <44 <20 Without chemotherapy, based on single study in patients without Whole organ 3D-CRT Edema V50 <27% <20 larynx cancer** Lung Whole organ 3D-CRT Symptomatic pneumonitis V20 # 30% <20 For combined lung. Gradual dose response Whole organ 3D-CRT Symptomatic pneumonitis Mean dose = 7 5 Excludes purposeful whole lung Whole organ 3D-CRT Symptomatic pneumonitis Mean dose = irradiation Whole organ 3D-CRT Symptomatic pneumonitis Mean dose = Whole organ 3D-CRT Symptomatic pneumonitis Mean dose = Whole organ 3D-CRT Symptomatic pneumonitis Mean dose = Esophagus Whole organ 3D-CRT Grade $3 acute esophagitis Mean dose < Based on RTOG and several studies Whole organ 3D-CRT Grade $2 acute esophagitis V35 <50% <30 A variety of alternate threshold doses have been implicated. Whole organ 3D-CRT Grade $2 acute esophagitis V50 <40% <30 Appears to be a dose/volume response Whole organ 3D-CRT Grade $2 acute esophagitis V70 <20% <30 Heart Pericardium 3D-CRT Pericarditis Mean dose <26 <15 Based on single study Pericardium 3D-CRT Pericarditis V30 <46% <15 Whole organ 3D-CRT Long-term cardiac mortality V25 <10% <1 Overly safe risk estimate based on model predictions S16 I. J. Radiation Oncology d Biology d Physics Volume 76, Number 3, Supplement, 2010 (Continued)
8 Table 1. QUANTEC Summary: Approximate Dose/Volume/Outcome Data for Several Organs Following Conventional Fractionation (Unless Otherwise Noted)* (Continued) Organ Volume segmented Irradiation type (partial organ unless otherwise stated) y Endpoint Dose (Gy), or dose/volume parameters y Rate (%) Notes on dose/volume parameters Liver Whole liver GTV 3D-CRT or Whole organ Classic RILD yy Mean dose <30-32 <5 Excluding patients with pre-existing liver disease or hepatocellular carcinoma, as tolerance doses are lower in these patients Whole liver GTV 3D-CRT Classic RILD Mean dose <42 <50 Whole liver GTV 3D-CRT or Whole organ Classic RILD Mean dose <28 <5 In patients with Child-Pugh A preexisting liver disease or hepatocellular carcinoma, excluding hepatitis B reactivation as an endpoint Whole liver GTV 3D-CRT Classic RILD Mean dose <36 <50 Whole liver GTV SBRT (hypofraction) Classic RILD Mean dose <13 <18 Whole liver GTV SBRT (hypofraction) Classic RILD Mean dose <15 <20 <5 <5 <5 <5 3 fractions, for primary liver cancer 6 fractions, for primary liver cancer 3 fractions, for liver metastases 6 fractions, for liver metastases >700 cc of normal liver SBRT (hypofraction) Classic RILD D max <15 <5 Critical volume based, in 3 5 fractions Kidney Bilateral whole kidney z Bilateral whole organ or 3D-CRT Clinically relevant renal dysfunction Bilateral whole kidney z Bilateral whole organ Clinically relevant renal dysfunction Bilateral whole kidney z 3D-CRT Clinically relevant renal dysfuntction Mean dose <15 18 <5 Mean dose <28 <50 V12 <55% <5 For combined kidney V20 <32% V23 <30% V28 <20% Stomach Whole organ Whole organ Ulceration D100 k <45 <7 Small bowel Individual small bowel loops 3D-CRT Grade $ 3 acute toxicity x V15 <120 cc <10 Volume based on segmentation of the individual loops of bowel, not the entire potential peritoneal space Entire potential space within peritoneal cavity 3D-CRT Grade $ 3 acute toxicity x V45 <195 cc <10 Volume based on the entire potential space within the peritoneal cavity (Continued) Use of NTCP models in the clinic d L. B. MARKS et al. S17
9 Organ Table 1. QUANTEC Summary: Approximate Dose/Volume/Outcome Data for Several Organs Following Conventional Fractionation (Unless Otherwise Noted)* (Continued) Volume segmented Irradiation type (partial organ unless otherwise stated) y Endpoint Rectum Whole organ 3D-CRT Grade $ 2 late rectal toxicity, Grade $ 3 late rectal toxicity Whole organ 3D-CRT Grade $ 2 late rectal toxicity, Grade $ 3 late rectal toxicity Whole organ 3D-CRT Grade $ 2 late rectal toxicity, Grade $ 3 late rectal toxicity Whole organ 3D-CRT Grade $ 2 late rectal toxicity, Grade $ 3 late rectal toxicity Whole organ 3D-CRT Grade $ 2 late rectal toxicity, Grade $ 3 late rectal toxicity Dose (Gy), or dose/volume parameters y Rate (%) V50 <50% <15 <10 V60 <35% <15 <10 V65 <25% <15 <10 V70 <20% <15 <10 V75 <15% <15 <10 Notes on dose/volume parameters Prostate cancer treatment Bladder Whole organ 3D-CRT Grade $ 3 late RTOG Dmax <65 <6 Bladder cancer treatment. Variations in bladder size/shape/ location during RT hamper ability to generate accurate data Whole organ 3D-CRT Grade $3 late RTOG V65 #50 % Prostate cancer treatment V70 #35 % V75 #25 % V80 #15 % Based on current RTOG 0415 recommendation Penile bulb Whole organ 3D-CRT Severe erectile dysfunction Mean dose to <35 95% of gland <50 Whole organ 3D-CRT Severe erectile dysfunction D90 k <50 <35 Whole organ 3D-CRT Severe erectile dysfunction D60-70 <70 <55 Abbreviations: 3D-CRT = 3-dimensional conformal radiotherapy, SRS = stereotactic radiosurgery, BED = Biologically effective dose, SBRT = stereotactic body radiotherapy, RILD = radiation-induced liver disease, RTOG = Radiation Therapy Oncology Group. * All data are estimated from the literature summarized in the QUANTEC reviews unless otherwise noted. Clinically, these data should be applied with caution. Clinicians are strongly advised to use the individual QUANTEC articles to check the applicability of these limits to the clinical situation at hand. They largely do not reflect modern IMRT. y All at standard fractionation (i.e., Gy per daily fraction) unless otherwise noted. Vx is the volume of the organ receiving $ x Gy. Dmax = Maximum radiation dose. z Non-TBI. x With combined chemotherapy. k Dx = minimum dose received by the hottest x% (or x cc s) of the organ. { Severe xerostomia is related to additional factors including the doses to the submandibular glands. ** Estimated by Dr. Eisbruch. yy Classic Radiation induced liver disease (RILD) involves anicteric hepatomegaly and ascites, typically occurring between 2 weeks and 3 months after therapy. Classic RILD also involves elevated alkaline phosphatase (more than twice the upper limit of normal or baseline value). zz For optic nerve, the cases of neuropathy in the 55 to 60 Gy range received z59 Gy (see optic nerve paper for details). Excludes patients with pituitary tumors where the tolerance may be reduced. S18 I. J. Radiation Oncology d Biology d Physics Volume 76, Number 3, Supplement, 2010
10 Use of NTCP models in the clinic d L. B. MARKS et al. S19 REFERENCES 1. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21: Kirkpatrick J, Meyer J, Marks L. The linear-quadratic model is inappropriate to model high-dose per fraction effects. Semin Radiat Oncol 2008;18: Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13: Langer M, Morrill SS, Lane R. A test of the claim that plan rankings are determined by relative complication and tumor-control probabilities. Int J Radiat Oncol Biol Phys 1998;41: Agren A, Brahme A, Turesson I. Optimization of uncomplicated control for head and neck tumors. Int J Radiat Oncol Biol Phys 1990;19: Miften MGO, Parda DS, Prosnitz RG, Marks LM. Using quality of life information to rationally incorporate normal tissue effects into treatment plan evaluation and scoring. In: Rubin PCL, Marks LB, Okunieff P, editors. Cured I lent. Late effects of cancer treatment on normal tissue. 1st ed. New York: Springer; Amols HI, Zaider M, Hayes MK, et al. Physician/patient-driven risk assignment in radiation oncology: Reality or fancy? Int J Radiat Oncol Biol Phys 1997;38: Morris DE. Clinical experience with retreatment for palliation. Semin Radiat Oncol 2000;10: Sadikov E, Bezjak A, Yi QL, et al. Value of whole brain re-irradiation for brain metastases single centre experience. Clin Oncol 2007;19: Kurup P, Reddy S, Hendrickson FR. Results of re-irradiation for cerebral metastases. Cancer 1980;46: Pfeffer MR, Rabin T, Tsvang L, et al. Orbital lymphoma: Is it necessary to treat the entire orbit? Int J Radiat Oncol Biol Phys 2004;60: Hope AJ, Lindsay PE, El Naqa I, et al. Clinical, dosimetric, and location-related factors to predict local control in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2005;63. S231 S Engels B, Soete G, Verellen D, et al. Conformal Arc Radiotherapy for Prostate Cancer: Increased Biochemical Failure in Patients With Distended Rectum on the Planning Computed Tomogram Despite Image Guidance by Implanted Markers. Int J Radiat Oncol Biol Phys 2009;74: Zagars GK, Schultheiss TE, Peters LJ. Inter-tumor heterogeneity and radiation dose-control curves. Radiother Oncol 1987;8: Jolles B. Area factor in skin reaction. Br Emp Cancer Campaign Rep 1939; Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 1985;8:S13 S Mohan R, Mageras GS, Baldwin B, et al. Clinically relevant optimization of 3-D conformal treatments. AAPM 1992;19: Niemierko A. A generalized concept of equivalent uniform dose (EUD). Med Phys 1999;26: Kutcher GJ, Burman C, Brewster L, et al. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys 1991;21: Burman C, Kutcher GJ, Emami B, et al. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991;21: Withers HR, Tayor JMG, Maciejewski B. Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys 1988;15: Jackson A, Ten Haken RK, Robertson JM, et al. Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys 1995;31: Niemierko A, Goitein M. Calculation of normal tissue complication probability and dose-volume histogram reduction schemes for tissues with a critical element architecture. Radiother Oncol 1991;20: Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for nonsmall cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45: El Naqa I, Bradley J, Blanco AI, et al. Multivariable modeling of radiotherapy outcomes including dose-volume and clinical factors. Int J Radiat Oncol Biol Phys 2006;64: Jackson A, Yorke E. NTCP and TCP for treatment planning. In: Memorial Sloan-Kettering Cancer Center, editor. A practical guide to intensity-modulated radiation therapy. Madison, WI: Medical Physics Pubishers; 2003; pp Deasy JO, Niemierko A, Herbert D, et al. Methodological issues in radiation dose-volume outcome analyses: Summary of a joint AAPM/NIH workshop. Med Phys 2002;29: Yorke ED. Modeling the effects of inhomogeneous dose distributions in normal tissues. Semin Radiat Oncol 2001;11: Moiseenko J, Deasy O, Van Dyk J. Radiobiological modeling for treatment planning. In: Van Dyk J, editor. The modern technology of radiation oncology: A compendium for medical physicists and radiation oncologists, vol. 2. Madison, WI: Medical Physics Publishing; 2005, pp
Predicting Normal Tissue Injury in the Modern era: An Update on QUANTEC
Predicting Normal Tissue Injury in the Modern era: An Update on QUANTEC Lawrence B. Marks, M.D. Professor and Chair University of North Carolina at Chapel Hill, NC 3D Hope Dose/volume Normal tissue outcome
More information8/16/2011. (Blanco et al. IJROBP 2005) (In press, IJROBP)
Methodological issues and key results in the QUANTEC 2010 review of quantitative analysis of normal tissue effects in the clinic (The QUANTEC steering committee:) Soeren Bentzen, Sandy Constine, Joe Deasy,
More informationOptimising Radiotherapy Using NTCP Models: 17 Years in Ann Arbor
Individualizing Optimizing Optimising Radiotherapy Using NTCP Models: 17 Years in Ann Arbor Randall K. Ten Haken, Ph.D. University of Michigan Department of Radiation Oncology Ann Arbor, MI Introduction
More informationAn update on NTCP data
An update on NTCP data Vladimir Semenenko, Ph.D. X. Allen Li, Ph.D. Department of Radiation Oncology Medical College of Wisconsin NCCAAPM 2006 Fall Meeting, October 3, 2006 Goal of Radiation Therapy Maximize
More informationDosimetric Uncertainties and Normal Tissue Tolerance. Ellen D Yorke Memorial Sloan Kettering Cancer Center New York City
Dosimetric Uncertainties and Normal Tissue Tolerance Ellen D Yorke Memorial Sloan Kettering Cancer Center New York City Traditional accuracy/precision goal is to deliver external beam radiation therapy
More informationPredicting Normal Tissue Injury in the Modern era: A Review of QUANTEC
Predicting Normal Tissue Injury in the Modern era: A Review of QUANTEC Lawrence B. Marks, M.D. University of North Carolina at Chapel Hill, NC Disclosures Grants: NIH, Lance Armstrong Advisor: Impac (Mosaiq)
More informationPredicting Normal Tissue Injury in the Modern era: A Review of QUANTEC
Predicting Normal Tissue Injury in the Modern era: A Review of QUANTEC Lawrence B. Marks, M.D. Professor and Chair University of North Carolina at Chapel Hill, NC Disclosures Grants: NIH, Lance Armstrong
More informationIMRT - the physician s eye-view. Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia
IMRT - the physician s eye-view Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia The goals of cancer therapy Local control Survival Functional status Quality of life Causes
More informationA new homogeneity index based on statistical analysis of the dose volume histogram
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 8, NUMBER 2, SPRING 2007 A new homogeneity index based on statistical analysis of the dose volume histogram Myonggeun Yoon, Sung Yong Park, a Dongho
More informationRanking radiotherapy treatment plans: physical or biological objectives?
Ranking radiotherapy treatment plans: physical or biological objectives? Martin Ebert Department of Radiation Oncology, Sir Charles Gairdner Hospital, Western Australia, Australia Background. The ranking
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationEvaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer
1 Charles Poole April Case Study April 30, 2012 Evaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer Abstract: Introduction: This study
More informationX. Allen Li BGRT. Biologically Based Treatment Planning. Biologically based treatment planning
Biologically Based Treatment Planning X. Allen Li AAPM Spring Clinical Meeting, March 20, 2012 Limitations of dose-volume based treatment planning DV metrics are merely surrogate measures of radiation
More informationThe dependence of optimal fractionation schemes on the spatial dose distribution
The dependence of optimal fractionation schemes on the spatial dose distribution Jan Unkelbach 1, David Craft 1, Ehsan Salari 1, Jagdish Ramakrishnan 1,2, Thomas Bortfeld 1 1 Department of Radiation Oncology,
More informationThe Physics of Oesophageal Cancer Radiotherapy
The Physics of Oesophageal Cancer Radiotherapy Dr. Philip Wai Radiotherapy Physics Royal Marsden Hospital 1 Contents Brief clinical introduction Imaging and Target definition Dose prescription & patient
More informationRecording Toxicity: the QUANTEC model. Michela Buglione di Monale Nadia Pasinetti Cattedra di Radioterapia
Recording Toxicity: the QUANTEC model Michela Buglione di Monale Nadia Pasinetti Cattedra di Radioterapia Brescia - September 30 th 2011 Breast cancer radiotherapy Many treated volumes Different treatment
More informationNovel techniques for normal tissue toxicity modelling. Laura Cella Institute of Biostructures and Bioimaging National Research Council of Italy
Novel techniques for normal tissue toxicity modelling Laura Cella Institute of Biostructures and Bioimaging National Research Council of Italy Disclosure: I have no conflict of interest An honorarium is
More informationBiologically Based Treatment Planning X. Allen Li
Biologically Based Treatment Planning X. Allen Li AAPM Spring Clinical Meeting, March 20, 2012 Limitations of dose-volume based treatment planning DV metrics are merely surrogate measures of radiation
More informationBiological/Clinical Outcome Models in RT Planning
Biological/Clinical Outcome Models in RT Planning Randy Ten Haken Ken Jee University of Michigan Why consider use of models? Are there problems that use of outcomes models could help resolve? Would their
More informationRADIOBIOLOIGCALLY BASED TREATMENT PLANNING: THE NEXT FRONTIER. Teddy LaMaster, MS
RADIOBIOLOIGCALLY BASED TREATMENT PLANNING: THE NEXT FRONTIER Teddy LaMaster, MS RADIOBIOLOGY Radiobiology is the interaction between ionizing radiation and living things. Varies for different cells, organs,
More informationEfficient SIB-IMRT planning of head & neck patients with Pinnacle 3 -DMPO
Investigations and research Efficient SIB-IMRT planning of head & neck patients with Pinnacle 3 -DMPO M. Kunze-Busch P. van Kollenburg Department of Radiation Oncology, Radboud University Nijmegen Medical
More informationSpinal Cord Doses in Palliative Lung Radiotherapy Schedules
Journal of the Egyptian Nat. Cancer Inst., Vol. 8, No., June: -, 00 Spinal Cord Doses in Palliative Lung Radiotherapy Schedules HODA AL-BOOZ, FRCR FFRRCSI M.D.* and CAROL PARTON, Ph.D.** The Departments
More informationTHE TRANSITION FROM 2D TO 3D AND TO IMRT - RATIONALE AND CRITICAL ELEMENTS
THE TRANSITION FROM 2D TO 3D AND TO IMRT - RATIONALE AND CRITICAL ELEMENTS ICTP SCHOOL ON MEDICAL PHYSICS FOR RADIATION THERAPY DOSIMETRY AND TREATMENT PLANNING FOR BASIC AND ADVANCED APPLICATIONS March
More informationRadiotherapy physics & Equipments
Radiotherapy physics & Equipments RAD 481 Lecture s Title: An Overview of Radiation Therapy for Health Care Professionals Dr. Mohammed Emam Vision :IMC aspires to be a leader in applied medical sciences,
More informationA SIMPLE METHOD OF OBTAINING EQUIVALENT DOSES FOR USE IN HDR BRACHYTHERAPY
PII S0360-3016(99)00330-2 Int. J. Radiation Oncology Biol. Phys., Vol. 46, No. 2, pp. 507 513, 2000 Copyright 2000 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/00/$ see front
More informationComparing conformal, arc radiotherapy and helical tomotherapy in craniospinal irradiation planning
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 15, NUMBER 5, 2014 Comparing conformal, arc radiotherapy and helical tomotherapy in craniospinal irradiation planning Pamela A. Myers, 1 Panayiotis Mavroidis,
More informationOutline. Contour quality control. Dosimetric impact of contouring errors and variability in Intensity Modulated Radiation Therapy (IMRT)
Dosimetric impact of contouring errors and variability in Intensity Modulated Radiation Therapy (IMRT) James Kavanaugh, MS DABR Department of Radiation Oncology Division of Medical Physics Outline Importance
More information4.1.1 Dose distributions LKB effective volume or mean liver dose? The critical volume model TUMOUR CONTROL...
1 CONTENTS 1 INTRODUCTION... 3 1.1 STEREOTACTIC BODY RADIATION THERAPY (SBRT)... 3 1.1.1 The development of SBRT... 3 1.1.2 The technique of SBRT... 4 1.1.3 Hypofractionation and inhomogeneous dose distribution...
More informationNCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)
BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,
More informationProject IX: Big Data Meets Medical Physics Dosimetry
Project IX: Big Data Meets Medical Physics Dosimetry Foundations and Recent Advances Fumbeya Marungo, Hilary Paisley, John Rhee Dr. Todd McNutt Dr. Scott Robertson Topic Goal improve radiotherapy risk
More informationOriginal Article. Teyyiba Kanwal, Muhammad Khalid, Syed Ijaz Hussain Shah, Khawar Nadeem
Original Article Treatment Planning Evaluation of Sliding Window and Multiple Static Segments Technique in Intensity Modulated Radiotherapy for Different Beam Directions Teyyiba Kanwal, Muhammad Khalid,
More informationRectal dose and toxicity dosimetric evaluation for various beam arrangements using pencil beam scanning protons with and without rectal spacers
Rectal dose and toxicity dosimetric evaluation for various beam arrangements using pencil beam scanning protons with and without rectal spacers 2015 MAC-AAPM Annual Meeting, Baltimore, MD Heeteak Chung,
More informationCorporate Medical Policy
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Abdomen and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis
More informationIntensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 03/01/2015 Section: Radiology
More informationTreatment Planning for Lung. Kristi Hendrickson, PhD, DABR University of Washington Dept. of Radiation Oncology
Treatment Planning for Lung Kristi Hendrickson, PhD, DABR University of Washington Dept. of Radiation Oncology Outline of Presentation Dosimetric planning strategies for SBRT lung Delivery techniques Examples
More informationDetermination and Use of Radiobiological Response Parameters in Radiation Therapy Optimization. Panayiotis Mavroidis
Determination and Use of Radiobiological Response Parameters in Radiation Therapy Optimization Panayiotis Mavroidis Division of Medical Radiation Physics Department of Oncology-Pathology Karolinska Institutet
More informationCorporate Medical Policy
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Head and Neck File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_head_and_neck
More informationChapter 2. Level II lymph nodes and radiation-induced xerostomia
Chapter 2 Level II lymph nodes and radiation-induced xerostomia This chapter has been published as: E. Astreinidou, H. Dehnad, C.H. Terhaard, and C.P Raaijmakers. 2004. Level II lymph nodes and radiation-induced
More informationDose prescription, reporting and recording in intensity-modulated radiation therapy: a digest of the ICRU Report 83
Special report Dose prescription, reporting and recording in intensity-modulated radiation therapy: a digest of the ICRU Report 83 Rapid development in imaging techniques, including functional imaging,
More informationDisclosure. Paul Medin teaches radiosurgery courses sponsored by BrainLAB Many animals (and humans) were harmed to make this presentation possible!
Disclosure The tolerance of the nervous system to SBRT: dogma, data and recommendations Paul Medin, PhD Paul Medin teaches radiosurgery courses sponsored by BrainLAB Many animals (and humans) were harmed
More informationDOSE AND VOLUME REDUCTION FOR NORMAL LUNG USING INTENSITY-MODULATED RADIOTHERAPY FOR ADVANCED-STAGE NON SMALL-CELL LUNG CANCER
doi:10.1016/j.ijrobp.2003.09.086 Int. J. Radiation Oncology Biol. Phys., Vol. 58, No. 4, pp. 1258 1267, 2004 Copyright 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/$ see front
More informationIntensity Modulated Radiation Therapy (IMRT)
Intensity Modulated Radiation Therapy (IMRT) Policy Number: Original Effective Date: MM.05.006 03/09/2004 Line(s) of Business: Current Effective Date: HMO; PPO 06/24/2011 Section: Radiology Place(s) of
More informationRadiotherapy Planning (Contouring Lung Cancer for Radiotherapy dose prescription) Dr Raj K Shrimali
Radiotherapy Planning (Contouring Lung Cancer for Radiotherapy dose prescription) Dr Raj K Shrimali Let us keep this simple and stick to some basic rules Patient positioning Must be reproducible Must be
More informationA STUDY OF PLANNING DOSE CONSTRAINTS FOR TREATMENT OF NASOPHARYNGEAL CARCINOMA USING A COMMERCIAL INVERSE TREATMENT PLANNING SYSTEM
doi:10.1016/j.ijrobp.2004.02.040 Int. J. Radiation Oncology Biol. Phys., Vol. 59, No. 3, pp. 886 896, 2004 Copyright 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/$ see front
More informationRadiotherapy Outcomes
in partnership with Outcomes Models with Machine Learning Sarah Gulliford PhD Division of Radiotherapy & Imaging sarahg@icr.ac.uk AAPM 31 st July 2017 Making the discoveries that defeat cancer Radiotherapy
More informationCitation Key for more information see:
Citation Key for more information see: http://open.umich.edu/wiki/citationpolicy Use + Share + Adapt { Content the copyright holder, author, or law permits you to use, share and adapt. } Public Domain
More informationDosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer
Dosimetric Analysis of 3DCRT or IMRT with Vaginal-cuff Brachytherapy (VCB) for Gynaecological Cancer Tan Chek Wee 15 06 2016 National University Cancer Institute, Singapore Clinical Care Education Research
More informationPotential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana
University of Groningen Potential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationTherapeutic ratio - An Overview. Past Present Future Prof Ramesh S Bilimaga
Therapeutic ratio - An Overview Past Present Future Prof Ramesh S Bilimaga Radiation Oncology Discipline of human medicine concerned with the generation, conservation and dissemination of knowledge concerning
More informationMarco Trovò CRO-Aviano
From pre-clinical research to clinical practice in radiation therapy: new predictive factors and biological markers to predict normal tissue toxicity after radiation therapy of the lung. Marco Trovò CRO-Aviano
More informationCardiovascular disease after radiation therapy
Cardiovascular disease after radiation therapy Giovanna Gagliardi Section of Radiotherapy Physics and Engineering Dept. of Medical Physics Karolinska University Hospital, Stockholm EU Scientific Seminar
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More informationPEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING
PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING ANATOMY ANATOMY CONT ANATOMY CONT. ANATOMY CONT. EYE OF A CHILD Normal tissue tolerance doses (in conventional #) TD 5/5 TD 50/5 Endpoint Gy Gy Optic nerve
More informationDosimetric Effects of Using Generalized Equivalent Uniform Dose (geud) in Plan Optimization
Dosimetric Effects of Using Generalized Equivalent Uniform Dose (geud) in Plan Optimization Ontida Apinorasethkul, MS, CMD AAMD Indianapolis June 14, 2017 Disclaimer This presentation is not sponsored
More informationPage 1. Helical (Spiral) Tomotherapy. UW Helical Tomotherapy Unit. Helical (Spiral) Tomotherapy. MVCT of an Anesthetized Dog with a Sinus Tumor
Helical (Spiral) Tomotherapy Novel Clinical Applications of IMRT Linac Ring Gantry CT Detector X-Ray Fan Beam Binary Multileaf Collimator Binary MLC Leaves James S Welsh, MS, MD Department of Human Oncology
More informationAccuracy Requirements and Uncertainty Considerations in Radiation Therapy
Departments of Oncology and Medical Biophysics Accuracy Requirements and Uncertainty Considerations in Radiation Therapy Introduction and Overview 6 August 2013 Jacob (Jake) Van Dyk Conformality 18 16
More informationFlattening Filter Free beam
Dose rate effect in external radiotherapy: biology and clinic Marta Scorsetti, M.D. Radiotherapy and Radiosurgery Dep., Istituto Clinico Humanitas, Milan, Italy Brescia October 8th/9th, 2015 Flattening
More informationEvaluation of Normal Tissue Complication Probability and Risk of Second Primary Cancer in Prostate Radiotherapy
Evaluation of Normal Tissue Complication Probability and Risk of Second Primary Cancer in Prostate Radiotherapy Rungdham Takam Thesis submitted for the degree of Doctor of Philosophy in The School of Chemistry
More informationAAPM WGSBRT NTCP Optic Apparatus (chiasm and nerve)
AAPM WGSBRT NTCP Optic Apparatus (chiasm and nerve) Michael T. Milano, MD PhD Department of Radiation Oncology University of Rochester, Rochester, NY 07/16/15 AAPM WGSBRT Optic Apparatus NTCP Issam El
More informationThe Four R s. Repair Reoxygenation Repopulation Redistribution. The Radiobiology of Small Fraction Numbers. The Radiobiology of Small Fraction Numbers
The Radiobiology of Small Fraction Numbers David J. Brenner, PhD, DSc Center for Radiological Research Columbia University Medical Center djb3@columbia.edu The Radiobiology of Small Fraction Numbers 1.
More informationKnowledge-Based IMRT Treatment Planning for Prostate Cancer: Experience with 101. Cases from Duke Clinic. Deon Martina Dick
Knowledge-Based IMRT Treatment Planning for Prostate Cancer: Experience with 101 Cases from Duke Clinic by Deon Martina Dick Department of Medical Physics Duke University Date: Approved: Joseph Lo, Chair
More informationAytul OZGEN 1, *, Mutlu HAYRAN 2 and Fatih KAHRAMAN 3 INTRODUCTION
Journal of Radiation Research, 2012, 53, 916 922 doi: 10.1093/jrr/rrs056 Advance Access Publication 21 August 2012 Mean esophageal radiation dose is predictive of the grade of acute esophagitis in lung
More informationGeometric dose prediction model for hemithoracic intensity-modulated radiation therapy in mesothelioma patients with two intact lungs
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 17, NUMBER 3, 2016 Geometric dose prediction model for hemithoracic intensity-modulated radiation therapy in mesothelioma patients with two intact lungs
More information8/2/2018. Acknowlegements: TCP SPINE. Disclosures
A Presentation for the AAPM Annual meeting, Aug 2, 2018 Nashville, TN Stereotactic Radiosurgery for Spinal Metastases: Tumor Control Probability Analyses and Recommended Reporting Standards for Future
More informationCorporate Medical Policy
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of the Chest File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_the_chest
More informationAssessing the shift of radiobiological metrics in lung radiotherapy plans using 2D gamma index
Original Article Assessing the shift of radiobiological metrics in lung radiotherapy plans using 2D gamma index Abdulhamid Chaikh, Jacques Balosso,2 Department of Radiation Oncology and Medical Physics,
More informationSBRT TREATMENT PLANNING: TIPS + TRICKS. Rachel A. Hackett CMD, RT(T)
SBRT TREATMENT PLANNING: TIPS + TRICKS Rachel A. Hackett CMD, RT(T) OUTLINE Brief radiobiology review 3D CRT Tx Planning VMAT Tx Planning Protocols Other Sites Oligomets Spine Liver Kidney Adrenal Gland
More informationIGRT Protocol Design and Informed Margins. Conflict of Interest. Outline 7/7/2017. DJ Vile, PhD. I have no conflict of interest to disclose
IGRT Protocol Design and Informed Margins DJ Vile, PhD Conflict of Interest I have no conflict of interest to disclose Outline Overview and definitions Quantification of motion Influences on margin selection
More informationClinical considerations of RBE in proton therapy
Clinical considerations of RBE in proton therapy H. Paganetti PhD Professor, Harvard Medical School Director of Physics Research, Massachusetts General Hospital, Radiation Oncology Why do we need the RBE
More informationReport of ICRU Committee on Volume and Dose Specification for Prescribing, Reporting and Recording in Conformal and IMRT A Progress Report
Report of ICRU Committee on Volume and Dose Specification for Prescribing, Reporting and Recording in Conformal and IMRT A Progress Report Paul M. DeLuca, Jr. 1, Ph.D., Vincent Gregoire 2, M.D., Ph.D.,
More informationClinical Implications Of Dose Summation And Adaptation
Clinical Implications Of Dose Summation And Adaptation Patrick Kupelian, M.D. Professor and Vice Chair University of California Los Angeles Department of Radiation Oncology pkupelian@mednet.ucla.edu August
More informationRe irradiation volumetric modulated arc therapy optimization based on cumulative biologically effective dose objectives
Received: 29 June 2018 Revised: 24 August 2018 Accepted: 27 August 2018 DOI: 10.1002/acm2.12481 TECHNICAL NOTE Re irradiation volumetric modulated arc therapy optimization based on cumulative biologically
More informationDefining Target Volumes and Organs at Risk: a common language
Defining Target Volumes and Organs at Risk: a common language Eduardo Rosenblatt Section Head Applied Radiation Biology and Radiotherapy (ARBR) Section Division of Human Health IAEA Objective: To introduce
More informationJOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 6, NUMBER 2, SPRING 2005
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 6, NUMBER 2, SPRING 2005 Advantages of inflatable multichannel endorectal applicator in the neo-adjuvant treatment of patients with locally advanced
More informationA TREATMENT PLANNING STUDY COMPARING VMAT WITH 3D CONFORMAL RADIOTHERAPY FOR PROSTATE CANCER USING PINNACLE PLANNING SYSTEM *
Romanian Reports in Physics, Vol. 66, No. 2, P. 394 400, 2014 A TREATMENT PLANNING STUDY COMPARING VMAT WITH 3D CONFORMAL RADIOTHERAPY FOR PROSTATE CANCER USING PINNACLE PLANNING SYSTEM * D. ADAM 1,2,
More informationRadiobiological Impact of Planning Techniques for Prostate Cancer in Terms of Tumor Control Probability and Normal Tissue Complication Probability
Original Article Radiobiological Impact of Planning Techniques for Prostate Cancer in Terms of Tumor Control Probability and Normal Tissue Complication Probability Rana S, Cheng CY Department of Medical
More informationCRT combined with a sequential VMAT boost in the treatment of upper thoracic esophageal cancer
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 14, NUMBER 5, 2013 CRT combined with a sequential VMAT boost in the treatment of upper thoracic esophageal cancer Xiance Jin, Jinling Yi, Yongqiang Zhou,
More informationFractionation: why did we ever fractionate? The Multiple Fractions School won! Survival curves: normal vs cancer cells
1 Basic Radiobiology for the Radiotherapy Physicist Colin G. Orton, Ph.D. Professor Emeritus, Wayne State University, Detroit, Michigan, USA Fractionation: why did we ever fractionate? Actually, initially
More informationRadiation Planning Index for dose distribution evaluation in stereotactic radiotherapy
Radiation Planning Index for dose distribution evaluation in stereotactic radiotherapy Krzysztof ŚLOSAREK, Aleksandra GRZĄDZIEL, Marta SZLAG, Joanna BYSTRZYCKA Received: 8.4.28 Accepted: 9.8.28 Subject:
More informationIndividualising prescription dose to lung tumours based on NTCP
Agenzia Provinciale per la Protonterapia Trento Individualising prescription dose to lung tumours based on NTCP M. Schwarz schwarz@atrep.it RT for the lung: where are we? Typical radical doses < 70 Gy
More informationTreatment Planning & IGRT Credentialing for NRG SBRT Trials
Treatment Planning & IGRT Credentialing for NRG SBRT Trials Hania Al Hallaq, Ph.D. Department of Radiation & Cellular Oncology The University of Chicago Learning Objectives Explain rationale behind credentialing
More informationBLADDER RADIOTHERAPY PLANNING DOCUMENT
A 2X2 FACTORIAL RANDOMISED PHASE III STUDY COMPARING STANDARD VERSUS REDUCED VOLUME RADIOTHERAPY WITH AND WITHOUT SYNCHRONOUS CHEMOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER (ISRCTN 68324339) BLADDER RADIOTHERAPY
More informationDosimetric Comparison of Intensity-Modulated Radiotherapy versus 3D Conformal Radiotherapy in Patients with Head and Neck Cancer
Dosimetric Comparison of Intensity-Modulated Radiotherapy versus 3D Conformal Radiotherapy in Patients with Head and Neck Cancer 1- Doaa M. AL Zayat. Ph.D of medical physics, Ayadi-Al Mostakbl Oncology
More informationPotential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana
University of Groningen Potential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationbiij Initial experience in treating lung cancer with helical tomotherapy
Available online at http://www.biij.org/2007/1/e2 doi: 10.2349/biij.3.1.e2 biij Biomedical Imaging and Intervention Journal CASE REPORT Initial experience in treating lung cancer with helical tomotherapy
More informationDoes the IMRT technique allow improvement of treatment plans (e.g. lung sparing) for lung cancer patients with small lung volume: a planning study
Does the IMRT technique allow improvement of treatment plans (e.g. lung sparing) for lung cancer patients with small lung volume: a planning study Received: 22.04.2008 Accepted: 4.07.2008 Subject: original
More informationRole of adaptive radiation therapy for pediatric patients with diffuse pontine glioma
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 12, NUMBER 2, spring 2011 Role of adaptive radiation therapy for pediatric patients with diffuse pontine glioma Chris Beltran, a Saumya Sharma, and Thomas
More informationChapter 7 General conclusions and suggestions for future work
Chapter 7 General conclusions and suggestions for future work Radiation therapy (RT) is one of the principle treatment modalities for the management of cancer. In recent decades, advances in the radiation
More informationFirst, how does radiation work?
Hello, I am Prajnan Das, Faculty Member in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center. We are going to talk today about some of the basic principles regarding
More informationReport on Radiation Disaster Recovery Studies
Report on Radiation Disaster Recovery Studies Course: Radiation Disaster Medicine Name: Uranchimeg Tsegmed Radiation Disaster Recovery Studies Nowadays, applications of nuclear technology in different
More informationGoals and Objectives: Head and Neck Cancer Service Department of Radiation Oncology
Goals and Objectives: Head and Neck Cancer Service Department of Radiation Oncology The head and neck cancer service provides training in the diagnosis, management, treatment, and follow-up care of head
More informationAdvances in external beam radiotherapy
International Conference on Modern Radiotherapy: Advances and Challenges in Radiation Protection of Patients Advances in external beam radiotherapy New techniques, new benefits and new risks Michael Brada
More informationA Dosimetric Comparison of Whole-Lung Treatment Techniques. in the Pediatric Population
A Dosimetric Comparison of Whole-Lung Treatment Techniques in the Pediatric Population Corresponding Author: Christina L. Bosarge, B.S., R.T. (R) (T) Indiana University School of Medicine Department of
More informationClinical Education A comprehensive and specific training program. carry out effective treatments from day one
Proton Therapy Clinical Education A comprehensive and specific training program carry out effective treatments from day one Forewarned is forearmed Although over 100,000 patients have been treated in proton
More informationA Comparison of Treatment Plans for Recurrent Nasopharyngeal Carcinoma
Chin J Radiol 23; 28: 285-292 285 A Comparison of Treatment Plans for Recurrent Nasopharyngeal Carcinoma WEI-CHUNG HSU 1 SZU-JUNG CHEN 2 KUNG-SHIH YING 3 CHIN-JYH JANG 1 PO-MING WANG 1 GAU-DE LIN 4 Department
More informationIMRT - Intensity Modulated Radiotherapy
IMRT - Intensity Modulated Radiotherapy Advanced product in the RT technology Aims to deliver radiation more precisely to the tumor, while relatively limiting dose to the surrounding normal tissues 7 position
More informationDose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed
Dose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed Take home message Preliminary data shows CRT technique in NSCLC allows dose escalation to an unprecedented level maintaining cancer
More informationEvaluation of Monaco treatment planning system for hypofractionated stereotactic volumetric arc radiotherapy of multiple brain metastases
Evaluation of Monaco treatment planning system for hypofractionated stereotactic volumetric arc radiotherapy of multiple brain metastases CASE STUDY Institution: Odette Cancer Centre Location: Sunnybrook
More informationRadiation Damage Comparison between Intensity Modulated Radiotherapy (IMRT) and Field-in-field (FIF) Technique In Breast Cancer Treatments
Radiation Damage Comparison between Intensity Modulated Radiotherapy () and Field-in-field (FIF) Technique In Breast Cancer Treatments Huisi Ai 1 and Hualin Zhang 2 1. Department of Radiation Oncology,
More informationTreatment Planning Evaluation of Volumetric Modulated Arc Therapy (VMAT) for Craniospinal Irradiation (CSI)
Treatment Planning Evaluation of Volumetric Modulated Arc Therapy (VMAT) for Craniospinal Irradiation (CSI) Tagreed AL-ALAWI Medical Physicist King Abdullah Medical City- Jeddah Aim 1. Simplify and standardize
More information